416 related articles for article (PubMed ID: 18668535)
21. A Novel Mutation in the Pyrin Domain of the NOD-like Receptor Family Pyrin Domain Containing Protein 3 in Muckle-Wells Syndrome.
Hu J; Zhu Y; Zhang JZ; Zhang RG; Li HM
Chin Med J (Engl); 2017 Mar; 130(5):586-593. PubMed ID: 28229991
[TBL] [Abstract][Full Text] [Related]
22. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.
Ilowite NT; Prather K; Lokhnygina Y; Schanberg LE; Elder M; Milojevic D; Verbsky JW; Spalding SJ; Kimura Y; Imundo LF; Punaro MG; Sherry DD; Tarvin SE; Zemel LS; Birmingham JD; Gottlieb BS; Miller ML; O'Neil K; Ruth NM; Wallace CA; Singer NG; Sandborg CI
Arthritis Rheumatol; 2014 Sep; 66(9):2570-9. PubMed ID: 24839206
[TBL] [Abstract][Full Text] [Related]
23. RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis.
Klein AL; Imazio M; Brucato A; Cremer P; LeWinter M; Abbate A; Lin D; Martini A; Beutler A; Chang S; Fang F; Gervais A; Perrin R; Paolini JF
Am Heart J; 2020 Oct; 228():81-90. PubMed ID: 32866928
[TBL] [Abstract][Full Text] [Related]
24. [CAPS: cryopyrin-associated periodic syndrome].
Saito MK
Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(5):369-77. PubMed ID: 22041424
[TBL] [Abstract][Full Text] [Related]
25. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.
Koné-Paut I; Lachmann HJ; Kuemmerle-Deschner JB; Hachulla E; Leslie KS; Mouy R; Ferreira A; Lheritier K; Patel N; Preiss R; Hawkins PN;
Arthritis Res Ther; 2011; 13(6):R202. PubMed ID: 22152723
[TBL] [Abstract][Full Text] [Related]
26. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.
Mitha E; Schumacher HR; Fouche L; Luo SF; Weinstein SP; Yancopoulos GD; Wang J; King-Davis S; Evans RR
Rheumatology (Oxford); 2013 Jul; 52(7):1285-92. PubMed ID: 23485476
[TBL] [Abstract][Full Text] [Related]
27. Interventions for reducing inflammation in familial Mediterranean fever.
Wu B; Xu T; Li Y; Yin X
Cochrane Database Syst Rev; 2015 Mar; (3):CD010893. PubMed ID: 25791871
[TBL] [Abstract][Full Text] [Related]
28. Molecule of the month. Rilonacept.
Drug News Perspect; 2008 May; 21(4):232. PubMed ID: 18560622
[No Abstract] [Full Text] [Related]
29. The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever.
Hashkes PJ; Spalding SJ; Hajj-Ali R; Giannini EH; Johnson A; Barron KS; Weisman MH; Pashinian N; Reiff AO; Samuels J; Wright D; Lovell DJ; Huang B
Biomed Res Int; 2014; 2014():854842. PubMed ID: 25147819
[TBL] [Abstract][Full Text] [Related]
30. NLRP3 A439V Mutation in a Large Family with Cryopyrin-associated Periodic Syndrome: Description of Ophthalmologic Symptoms in Correlation with Other Organ Symptoms.
Sobolewska B; Angermair E; Deuter C; Doycheva D; Kuemmerle-Deschner J; Zierhut M
J Rheumatol; 2016 Jun; 43(6):1101-6. PubMed ID: 27134254
[TBL] [Abstract][Full Text] [Related]
31. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.
Hawkins PN; Lachmann HJ; Aganna E; McDermott MF
Arthritis Rheum; 2004 Feb; 50(2):607-12. PubMed ID: 14872505
[TBL] [Abstract][Full Text] [Related]
32. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome--description of a heterogeneous phenotype and response to treatment.
Kuemmerle-Deschner JB; Lohse P; Koetter I; Dannecker GE; Reess F; Ummenhofer K; Koch S; Tzaribachev N; Bialkowski A; Benseler SM
Arthritis Res Ther; 2011; 13(6):R196. PubMed ID: 22146561
[TBL] [Abstract][Full Text] [Related]
33. Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial.
Mantero JC; Kishore N; Ziemek J; Stifano G; Zammitti C; Khanna D; Gordon JK; Spiera R; Zhang Y; Simms RW; Lafyatis R
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):146-149. PubMed ID: 30277862
[TBL] [Abstract][Full Text] [Related]
34. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes.
Lachmann HJ; Lowe P; Felix SD; Rordorf C; Leslie K; Madhoo S; Wittkowski H; Bek S; Hartmann N; Bosset S; Hawkins PN; Jung T
J Exp Med; 2009 May; 206(5):1029-36. PubMed ID: 19364880
[TBL] [Abstract][Full Text] [Related]
35. [Syndrome of Muckle-Wells and autoinflammatory familiar syndrome induced by cold].
Calvo Penadés I; López Montesinos B; Marco Puche A
Med Clin (Barc); 2011 Jan; 136 Suppl 1():16-21. PubMed ID: 21596182
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome.
Kuemmerle-Deschner JB; Tyrrell PN; Koetter I; Wittkowski H; Bialkowski A; Tzaribachev N; Lohse P; Koitchev A; Deuter C; Foell D; Benseler SM
Arthritis Rheum; 2011 Mar; 63(3):840-9. PubMed ID: 21360513
[TBL] [Abstract][Full Text] [Related]
37. Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD).
Radin A; Marbury T; Osgood G; Belomestnov P
J Clin Pharmacol; 2010 Jul; 50(7):835-41. PubMed ID: 20035038
[TBL] [Abstract][Full Text] [Related]
38. A cryopyrin-associated periodic syndrome with joint destruction.
Lequerré T; Vittecoq O; Saugier-Veber P; Goldenberg A; Patoz P; Frébourg T; Le Loët X
Rheumatology (Oxford); 2007 Apr; 46(4):709-14. PubMed ID: 17178739
[TBL] [Abstract][Full Text] [Related]
39. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes.
Maksimovic L; Stirnemann J; Caux F; Ravet N; Rouaghe S; Cuisset L; Letellier E; Grateau G; Morin AS; Fain O
Rheumatology (Oxford); 2008 Mar; 47(3):309-10. PubMed ID: 18174231
[TBL] [Abstract][Full Text] [Related]
40. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.
Lovell DJ; Giannini EH; Reiff AO; Kimura Y; Li S; Hashkes PJ; Wallace CA; Onel KB; Foell D; Wu R; Biedermann S; Hamilton JD; Radin AR
Arthritis Rheum; 2013 Sep; 65(9):2486-96. PubMed ID: 23754188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
